Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine dosing for prevention of remifentanil-induced hyperalgesia after thyroidectomy
ChiCTR2200060741Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in postoperative pain and opioid-induced hyperalgesia (OIH) (4 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Mechanical withdrawal threshold. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postoperative painopioid-induced hyperalgesia (OIH)
Beyond the preview
Go deeper on ChiCTR2200060741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060741.